TY - GEN
T1 - CERN-MEDICIS: A unique facility for the production of nonconventional radionuclides for the medical research
AU - Duchemin, Charlotte
AU - Fernandes Pinto Ramos, João Pedro
AU - Stora, Thierry
AU - Aubert, A.
AU - Barbero, Ermano
AU - Barozier, Vincent
AU - Bernardes, Ana-Paula
AU - Bertreix, Philippe
AU - Burnel, D.
AU - Catherall, Richard
AU - Cirilli, M.
AU - Cocolios, Thomas Elias
AU - Compte, J.
AU - Crepieux, Bernard
AU - Deschamps, Matthieu
AU - Dockx, Kristof
AU - Dorsival, Alexandre
AU - Fedosseev, Valentin N.
AU - Fernier, P.
AU - Formento-Cavaier, Roberto
AU - Gilardoni, Simone
AU - Grenard, Jean-Louis
AU - Haddad, Ferid
AU - Reinhard, Heinke
AU - Khan, Moazam
AU - Koester, Ulli
AU - Lambert, Laura
AU - Lili, Giordano
AU - Giacomo, Lunghi
AU - Marsh, Bruce A
AU - Martinez, Palenzuela
AU - Pozzi, Fabio
AU - Riegert, Julien
AU - Rothe, Sebastian
AU - Riccardi, Francesco
AU - Riggaz, Nicolas
AU - Stegemann, Simon
AU - Talip, Zenip
AU - Thiboud, Julien
AU - van der Meulen, Nicholas P.
AU - Vollaire, Joachim
AU - Vuong, Nhat-Tan
N1 - Score=3
PY - 2020/10/10
Y1 - 2020/10/10
N2 - CERN-MEDICIS (MEDical Isotopes Collected from ISolde) is a facility at CERN (Switzerland) dedicated to the production of non-conventional radionuclides for research and development in imaging, diagnostics and radiation therapy done at partner institutes. It exploits, in a controlled radiation area suited for the handling of unsealed radioactive sources, a target irradiation station positioned between the High Resolution Separator (HRS) ISOLDE target station and its beam dump, a target remote handling system and a dedicated isotope separator beam line. It irradiates targets with the 1.4 GeV Proton Synchroton Booster (PSB), and also receives activated target materials from external institutes, notably during CERN’s Long Shut-Downs. The irradiated target is heated to high temperatures (up to 2300°C) to allow for the release of the isotopes of interest out of the target which are subsequently ionized. The ions are accelerated and the beam is steered through an offline mass separator. The radionuclide batches are, this way, extracted through mass separation and implanted into a thin metallic collection foil up to an energy of 60 keV. After collection, the isotope source is prepared to be dispatched to biomedical research centers. Since its commissioning in December 2017, the CERN-MEDICIS facility has provided non-conventional medical radionuclides such as Tb-149, Tb-152, Tb-155, Tm-165, Er-169 and Yb-175 with high specific activity, some for the first time, to research institutes and hospitals, being part of the MEDICIS collaboration, for R&D in imaging or treatment.
AB - CERN-MEDICIS (MEDical Isotopes Collected from ISolde) is a facility at CERN (Switzerland) dedicated to the production of non-conventional radionuclides for research and development in imaging, diagnostics and radiation therapy done at partner institutes. It exploits, in a controlled radiation area suited for the handling of unsealed radioactive sources, a target irradiation station positioned between the High Resolution Separator (HRS) ISOLDE target station and its beam dump, a target remote handling system and a dedicated isotope separator beam line. It irradiates targets with the 1.4 GeV Proton Synchroton Booster (PSB), and also receives activated target materials from external institutes, notably during CERN’s Long Shut-Downs. The irradiated target is heated to high temperatures (up to 2300°C) to allow for the release of the isotopes of interest out of the target which are subsequently ionized. The ions are accelerated and the beam is steered through an offline mass separator. The radionuclide batches are, this way, extracted through mass separation and implanted into a thin metallic collection foil up to an energy of 60 keV. After collection, the isotope source is prepared to be dispatched to biomedical research centers. Since its commissioning in December 2017, the CERN-MEDICIS facility has provided non-conventional medical radionuclides such as Tb-149, Tb-152, Tb-155, Tm-165, Er-169 and Yb-175 with high specific activity, some for the first time, to research institutes and hospitals, being part of the MEDICIS collaboration, for R&D in imaging or treatment.
KW - Radionuclides
KW - CERN
KW - Medical isotopes
KW - ISOLDE
UR - https://ecm.sckcen.be/OTCS/llisapi.dll/open/42127935
M3 - In-proceedings paper
SN - 9783954502134
SP - 75
EP - 79
BT - MC8: Applications ofAccelerators, Technology Transfer, Industrial Relations and Outreach
PB - JACoW Publishing
T2 - 2020 - IPAC
Y2 - 10 May 2020 through 15 May 2020
ER -